Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-Resistant Prostate Cancer
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
- Trial name
- NCT02711956
- Testing
- ZEN003694, Enzalutamide
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Zenith Epigenetics
Prostate Cancer
Metformin in Castration-Resistant Prostate Cancer
Metformin is a medication that is prescribed for people with diabetes to help the body respond better to its own insulin and decrease sugar production by the liver.
- Trial name
- NCT01215032
- Testing
- Metformin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Bone Metastases, Castration-Resistant Prostate Cancer
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and…
- Trial name
- NCT01106352
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Where
- 7 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Bayer
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred…
- Trial name
- NCT04089553
- Testing
- AZD4635, Oleclumab, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
- Trial name
- SPARTAN (NCT01946204)
- Testing
- Apalutamide
- Where
- 379 sites in United States, Australia and 23 more
- Volunteers
- 1,207 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Metastatic Castration Resistant Prostate Cancer
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer)…
- Trial name
- PRESIDE (NCT02288247)
- Testing
- Enzalutamide, Docetaxel, Prednisolone
- Where
- 89 sites in Austria, Belgium and 14 more
- Volunteers
- 688 people
- Sponsor
- Astellas Pharma Europe Ltd.
Prostate Adenocarcinoma
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer.
- Trial name
- NCT04288687
- Testing
- Niraparib Pill
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20 mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic…
- Trial name
- FIRSTANA (NCT01308567)
- Testing
- Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
- Where
- 167 sites in United States, Australia and 23 more
- Volunteers
- 1,168 people
- Sponsor
- Sanofi
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Prostatic Neoplasms
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01020305
- Testing
- Temsirolimus, Casodex (bicalutamide)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sandy Srinivas
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
This phase III study provides access to 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) imaging for patients with castrate-resistant prostate cancer that has spread to other places in the body…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05547386
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Mayo Clinic
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Prostate Cancer
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
The purpose of this study is to find the highest dose level of the study drug, 177Lu-PSMA-617 that can be given without severe side effects for advanced prostate cancer.
- Trial name
- NCT03042468
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-HBED-CC
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Metastatic Castration-Resistant Prostate Cancer
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
- Trial name
- CYCLONE 1 (NCT04408924)
- Testing
- Abemaciclib
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with…
- Trial name
- eRADicAte (NCT02097303)
- Testing
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Carolina Research Professionals, LLC
Prostatic Neoplasms
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in…
- Trial name
- NCT00473512
- Testing
- Abiraterone acetate, Abiraterone acetate MTD, Dexamethasone
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Cougar Biotechnology, Inc.
Metastatic Castration Resistant Prostate Cancer (mCRPC)
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
This was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer.
- Trial name
- NCT03480646
- Testing
- CPI-1205, Cobicistat, Enzalutamide
- Where
- 41 sites in United States
- Volunteers
- 175 people
- Sponsor
- Constellation Pharmaceuticals